Mashiba H, Matsunaga K
Division of Immunology, National Kyushu Cancer Center, Fukuoka, Japan.
Eur Cytokine Netw. 1991 May-Jun;2(3):195-9.
We have attempted to augment specifically the antiproliferative effect of recombinant human lymphotoxin (rhLT) on tumor cells in combined use with diethyldithiocarbamate (DDC) which is known to inactivate superoxide dismutase. For this purpose, anti-Meth A tumor cell antibody-DDC conjugates were used to confer the selectivity on the augmented antiproliferative effect in combined use of rhLT with DDC. Simultaneous addition of rhLT (1 u/ml to 100 u/ml) with the diluted conjugates to the target Meth A tumor cells induced the augmentation of the antiproliferative effect although antibody control was not effective. Similar augmentation of the antiproliferative effect was obtained when the target cells were treated with the conjugates prior to the addition of rhLT although the rate of inhibition was low. This approach seems to be useful because the antiproliferative effect of LT on target tumor cells could be augmented and side effects of LT could be avoided.
我们试图通过与已知能使超氧化物歧化酶失活的二乙基二硫代氨基甲酸盐(DDC)联合使用,来增强重组人淋巴毒素(rhLT)对肿瘤细胞的抗增殖作用。为此,抗Meth A肿瘤细胞抗体-DDC偶联物被用于在rhLT与DDC联合使用时赋予增强的抗增殖作用以选择性。将rhLT(1单位/毫升至100单位/毫升)与稀释后的偶联物同时添加到靶标Meth A肿瘤细胞中,可诱导抗增殖作用增强,尽管抗体对照无效。当在添加rhLT之前先用偶联物处理靶细胞时,也可获得类似的抗增殖作用增强,尽管抑制率较低。这种方法似乎很有用,因为LT对靶标肿瘤细胞的抗增殖作用可以增强,并且可以避免LT的副作用。